Compounded semaglutide
Sold by Aspire Health · Injection, vial · every compounded semaglutide record
Price
| Term | Published rate | Charged today |
|---|---|---|
| One vial; 0.25 mg weekly dose; 10 weeks supply Price conditions have not been established; the quoted figure is not a verified recurring rate. Clinician-selected weekly dose and exact vial; medication price excludes required $49/every 28-day care and any separately charged services. “0.25 mg 10 weeks $129 $258 $387” | $129Published figure | Charged todayNot verified |
| One vial; 0.5 mg weekly dose; 5 weeks supply Price conditions have not been established; the quoted figure is not a verified recurring rate. Clinician-selected weekly dose and exact vial; medication price excludes required $49/every 28-day care and any separately charged services. “0.5 mg 5 weeks $129 $258 $387” | $129Published figure | Charged todayNot verified |
| One vial; 1 mg† weekly dose; 5 weeks supply Price conditions have not been established; the quoted figure is not a verified recurring rate. Clinician-selected weekly dose and exact vial; medication price excludes required $49/every 28-day care and any separately charged services. “1 mg† 5 weeks $159 $318 $477” | $159Published figure | Charged todayNot verified |
| One vial; 1.7 mg† weekly dose; 5.8 weeks supply Price conditions have not been established; the quoted figure is not a verified recurring rate. Clinician-selected weekly dose and exact vial; medication price excludes required $49/every 28-day care and any separately charged services. “1.7 mg† 5.8 weeks $189 $378 $499” | $189Published figure | Charged todayNot verified |
| One vial; 2.4 mg† weekly dose; 4.1 weeks supply Price conditions have not been established; the quoted figure is not a verified recurring rate. Clinician-selected weekly dose and exact vial; medication price excludes required $49/every 28-day care and any separately charged services. “2.4 mg† 4.1 weeks $189 $378 $499” | $189Published figure | Charged todayNot verified |
Price sources
- One vial; 0.25 mg weekly dose; 10 weeks supply · aspirehealth.care — read October 2026
- One vial; 0.5 mg weekly dose; 5 weeks supply · aspirehealth.care — read October 2026
- One vial; 1 mg† weekly dose; 5 weeks supply · aspirehealth.care — read October 2026
- One vial; 1.7 mg† weekly dose; 5.8 weeks supply · aspirehealth.care — read October 2026
- One vial; 2.4 mg† weekly dose; 4.1 weeks supply · aspirehealth.care — read October 2026
We earn nothing from this link. It opens Aspire Health's website without a paid referral.
History
Fewer than two comparable calendar-month readings are available for a price trend. Day- or week-based supplies, introductory offers and unverified payment terms are not connected in this chart.
- September 2026 — Entry added to the register
Sourcing and terms
| Pharmacy | Strive Pharmacy / Boudreaux’s New Drug Store / Rush Pharmacy (publicly listed network; individual assignment unconfirmed) |
|---|---|
| States | Not disclosed |
| Prescriber | Both |
| Cancellation | Cancel care by emailing info@aspirehealth.care; cancellation takes effect at the end of the paid billing cycle, without partial-period refunds except as required by law. Consultation services are generally nonrefundable after clinical review, including denial of a requested treatment. The medication-ordering FAQ makes compounded charges nonrefundable once the prescription is sent to the pharmacy, while general terms describe final medication sales after shipment, with stated error exceptions. Cancel auto-refills before renewal or switch to manual refills. https://aspirehealth.care/faq/ |
| Membership | Required. $49 every 28 days. The FAQ explicitly requires $49 every 28 days for Weight Management, starting at enrollment, separately from medication. The main page calls it $49 Monthly Medical Care; its generic monthly wording is not used to convert the specific 28-day cycle into a calendar month. https://aspirehealth.care/faq/ https://aspirehealth.care/weight-loss/ |
| Consult fee | None. “The actual main weight-management page explicitly advertises a free new-patient consultation. Ongoing medical care and medication are separately charged; this does not claim all later services are free.” |
Recorded from aspirehealth.care. Unlike the price rows above, these carry a summary rather than a word-for-word quotation, so they are not shown in quotation marks.
Notes
- 1. September 2026 — Aspire Health states two different, unreconciled monthly non-medication fees: the semaglutide and tirzepatide product pages each say 'Monthly Medical Care: $49 — Includes provider visits, messaging, prescription management, and ongoing medical support. Medication priced separately (see tables above)', while the FAQ separately describes a 'LoseIt Program' at $75/month whose active enrollment 'is required to continue medication therapy.' Neither page mentions or reconciles the other figure. The membership entry above uses the $75 LoseIt Program figure since it is the one explicitly tied to required enrollment; the $49 'Monthly Medical Care' quote ('Monthly Medical Care: $49') from https://aspirehealth.care/tirzepatide-for-weight-loss/ and https://aspirehealth.care/semaglutide-for-medical-weight-management/ is flagged here rather than recorded a second time. Separately, https://aspirehealth.care/service-areas/ lists 49 state names (every state except Alabama) grouped as 'Western/Central/Eastern States,' but the page explains these are color-coded on an interactive map as 'Currently Licensed' vs. 'Coming Soon' — this text-extraction tool cannot read the map's color-coding, so which of the 49 are actually served today could not be confirmed; states.list is left empty rather than asserting all 49 as current coverage. The Wegovy/Zepbound dose tables are captioned 'Pricing varies based on insurance coverage. Patients should verify benefits directly with their insurance provider,' so it is unclear whether the listed dollar figures are a cash-pay price or already insurance-adjusted; recorded as-is with that caveat rather than labeled 'cash price'.
- 2. October 2026 — The current dose table identifies actual compounded medication vials, with one-, two- and three-vial prices and dose-dependent supplies measured in weeks. One-vial prices are recorded without converting weeks to months; multi-vial totals remain source-specific catalog variants. The/B3 heading is printed by the provider; confirm the exact formula on the pharmacy label. https://aspirehealth.care/semaglutide-for-medical-weight-management/
- 3. October 2026 — Required care is $49 every 28 days, separately from medication. The current FAQ replaces the older $75/month figure. The public pharmacy list names Strive Pharmacy, Boudreaux’s New Drug Store and Rush Pharmacy (Florida and Texas locations); it does not establish which will fill a particular prescription. The fully loaded service map identifies licensed versus coming-soon states by color. A conservative affirmative subset of 31 clearly blue states is recorded; small ambiguous labels are not asserted. https://aspirehealth.care/faq/ https://aspirehealth.care/service-areas/
- 4. October 2026 — The page suggests discussing retatrutide after a plateau, but does not establish a separately specified, priced program, preparation or pharmacy. This mention is not treated as a verified additional active product or an approval claim. https://aspirehealth.care/semaglutide-for-medical-weight-management/
- 5. October 2026 — The main weight-loss page explicitly advertises a free new-patient consultation and $49 Monthly Medical Care, while the FAQ states $49 every 28 days. The exact FAQ cycle is retained; a 28-day cycle is not a calendar month. General legal language about consultation fees does not override the explicit free initial consultation offer. https://aspirehealth.care/weight-loss/ https://aspirehealth.care/faq/
- 6. October 2026 — The fully loaded public map marks these 31 clearly identifiable states blue under its Currently Licensed legend: Alaska, Arizona, Colorado, Florida, Hawaii, Idaho, Illinois, Iowa, Kansas, Kentucky, Louisiana, Maine, Massachusetts, Michigan, Minnesota, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Mexico, New York, North Dakota, Oklahoma, South Dakota, Utah, Vermont, Virginia, Washington, Wisconsin, Wyoming. This is a conservative licensure subset, not an exhaustive roster or confirmation that this medication is available in each state. Tiny Delaware, Maryland and District of Columbia markings were not classified. Drug, provider and pharmacy restrictions still apply; full program coverage is not established. https://aspirehealth.care/service-areas/
6 further notes concern other Aspire Health programs and sit on the provider record.
Treatment Registry is an independent editorial record. It is not a government registry, a licensing body, or a certification. An entry means we recorded what a company published on a given date. It does not mean we recommend the program, and it does not mean the program is approved by anyone.